CANCER IMMUNOLOGY (CI) Over the past decade, immunotherapy has emerged as an established modality that is revolutionizing the treatment of many cancers. The Cancer Immunology (CI) Research Program has focused on genetically manipulating T cells, applying new principles of synthetic biology, and combining engineered T cells with small molecules and antibodies to broaden the applications and improve the safety and efficacy of adoptive immunotherapy. Despite the success achieved with immunologic approaches in treating some malignancies, major gaps exist in our current understanding of the complex relationship between progressing tumors and host immunity, and these must be understood and overcome to achieve the potential of immunotherapy in many common cancers. The CI program will focus on systematically tackling these barriers to eradicating tumors using a variety of immunotherapeutic modalitie alone and in combination.
The specific aims of CI are (1) to develop effective and safe cellular immunotherapies for adult and pediatric hematologic malignancies and solid tumors, (2) to identify and overcome the barriers to immune-mediated tumor eradication using clinical specimens and preclinical models, (3) to translate discoveries in basic immunology and synthetic biology to novel clinical applications in cancer immunotherapy. The Cancer Immunology (CI) program currently has 39 members from 11 departments and divisions and 4 Consortium institutions. Nineteen members have primary appointments at Fred Hutch, 12 members at University of Washington, and 8 members at Seattle Children?s. Fourteen new faculty members joined this program in the last cycle. The current research support of CI members is $23.4M (direct costs) in research grant funding, of which $4.4M (19%) is from the NCI and $7.8M (33%) is peer reviewed. The Cancer Immunology program published a total of 470 papers in the last grant period, of which 14% were intra- programmatic, 49% were inter-programmatic, and 50% had external co-authors. Program members have utilized all 12 of the Consortium Shared Resources. This P30 grant also assists this program by providing administrative and logistical support for CI meetings, pilot funding for new research projects, and recruitment resources for new faculty.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Hempstead, Bridgette; Green, Cynthia; Briant, Katherine J et al. (2018) Community Empowerment Partners (CEPs): A Breast Health Education Program for African-American Women. J Community Health 43:833-841
OhAinle, Molly; Helms, Louisa; Vermeire, Jolien et al. (2018) A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV. Elife 7:
Syrjala, Karen L; Yi, Jean C; Artherholt, Samantha B et al. (2018) An online randomized controlled trial, with or without problem-solving treatment, for long-term cancer survivors after hematopoietic cell transplantation. J Cancer Surviv 12:560-570
Liu, Yang; He, Qianchan; Sun, Wei (2018) Association analysis using somatic mutations. PLoS Genet 14:e1007746
Glaser, Adam K; Chen, Ye; Yin, Chengbo et al. (2018) Multidirectional digital scanned light-sheet microscopy enables uniform fluorescence excitation and contrast-enhanced imaging. Sci Rep 8:13878
Liu, Yanyan; Xiong, Sican; Sun, Wei et al. (2018) Joint Analysis of Strain and Parent-of-Origin Effects for Recombinant Inbred Intercrosses Generated from Multiparent Populations with the Collaborative Cross as an Example. G3 (Bethesda) 8:599-605
Mora-Pinzon, Maria C; Trentham-Dietz, Amy; Gangnon, Ronald E et al. (2018) Urinary Magnesium and Other Elements in Relation to Mammographic Breast Density, a Measure of Breast Cancer Risk. Nutr Cancer 70:441-446
Shirts, Brian H; Konnick, Eric Q; Upham, Sarah et al. (2018) Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes. Am J Hum Genet 103:19-29
Du, Jing; Flynn, Ryan; Paz, Katelyn et al. (2018) Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. Blood 131:1743-1754
Suzuki, Aussie; Gupta, Amitabha; Long, Sarah K et al. (2018) A Kinesin-5, Cin8, Recruits Protein Phosphatase 1 to Kinetochores and Regulates Chromosome Segregation. Curr Biol 28:2697-2704.e3

Showing the most recent 10 out of 1267 publications